T2 Biosystems’ Bacteria Panel Wins “Best New Technology Solution - Diagnostics" Award in MedTech Breakthrough Awards
May 19 2020 - 8:30AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens, today announced it won the
“Best New Technology Solution - Diagnostics" award for its
T2Bacteria® Panel solution in the fourth annual MedTech
Breakthrough Awards program.
The awards program, which received thousands of
nominations from companies across the globe, “recognizes the
top companies, people, platforms and products in the health,
fitness and medical technology industries today,” according to its
website.
“We’re honored to be recognized by the MedTech Breakthrough
Awards and grateful to the judges who recognize the importance of
rapid identification of sepsis-causing pathogens in order to
effectively and efficiently treat patients with bloodstream
infections, which can lead to sepsis,” said John Sperzel, President
and Chief Executive Officer of T2 Biosystems.
Sperzel continued, “According to the Centers for Disease Control
and Prevention, each year at least 1.7 million adults in America
develop sepsis and nearly 270,000 Americans die as a result. But,
with swift diagnosis and treatment, which our T2Bacteria Panel
helps facilitate, we can help reduce these numbers for patients
with bloodstream infections and improve patient outcomes.”
The T2Bacteria Panel, which was FDA cleared in May 2018, can
detect sepsis-causing bacterial pathogens directly from whole blood
in three to five hours, without the need to wait for a blood
culture, which typically takes days to provide results and is not
as sensitive. By providing quicker results, the T2Bacteria Panel
can help clinicians start patients on the right therapy sooner,
which can lead to a series of potential benefits, including
improved patient outcomes, better management of antibiotics,
reduced length of stay in the hospital and more.
The MedTech Breakthrough Award is one more addition to the
Company’s growing list of accolades and milestones. Most recently,
T2 Biosystems announced it was awarded an Innovative Technology
contract from Vizient, Inc., the largest member-driven health care
performance improvement company in the country, covering its T2Dx®
Instrument, as well as the T2Bacteria and T2Candida® Panels.
About T2 Biosystems T2 Biosystems, a
leader in the rapid detection of sepsis-causing pathogens, is
dedicated to improving patient care and reducing the cost of care
by helping clinicians effectively treat patients faster than ever
before. T2 Biosystems’ products include the T2Dx® Instrument,
T2Candida® Panel, the T2Bacteria® Panel, and the
T2Resistance™ Panel and are powered by the proprietary T2
Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active
pipeline of future products, including the T2Cauris™ Panel,
T2SARS-CoV-2™ Panel, and T2Lyme™ Panel, as well as
additional products for the detection of bacterial and fungal
pathogens and associated antimicrobial resistance markers, as well
as biothreat pathogens.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, without limitation, statements regarding additional
patients, timing of testing patients, anticipated product benefits,
strategic priorities, product expansion or opportunities, growth
expectations or targets, timing of FDA filings or clearances and
anticipated operating expenses, as well as statements that include
the words “expect,” “intend,” “plan,” “believe,” “project,”
“forecast,” “estimate,” “may,” “should,” “anticipate,” and similar
statements of a future or forward looking nature. These
forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other
important factors that may cause actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, (i) any
inability to (a) realize anticipated benefits from commitments,
contracts or products; (b) successfully execute strategic
priorities; (c) bring products to market; (d) expand product usage
or adoption; (e) obtain customer testimonials; (f) accurately
predict growth assumptions; (g) realize anticipated revenues; (h)
incur expected levels of operating expenses; or (i) increase the
number of high-risk patients at customer facilities; (ii) failure
of early data to predict eventual outcomes; (iii) failure to
make or obtain anticipated FDA filings or clearances within
expected time frames or at all; or (iv) the factors discussed under
Item 1A. "Risk Factors" in the company's Annual Report on Form 10-K
for the year ended December 31, 2019, filed with the U.S.
Securities and Exchange Commission, or SEC, on March 16, 2020, and
other filings the company makes with the SEC from time to time.
These and other important factors could cause actual results to
differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management's estimates as of the date of this
press release. While the company may elect to update such
forward-looking statements at some point in the future, unless
required by law, it disclaims any obligation to do so, even if
subsequent events cause its views to change. Thus, no one should
assume that the Company’s silence over time means that actual
events are bearing out as expressed or implied in such
forward-looking statements. These forward-looking statements should
not be relied upon as representing the company's views as of any
date subsequent to the date of this press release.
Media Contact: Gina Kent, Vault
Communications gkent@vaultcommunications.com
610-455-2763
Investor Contact: Philip Trip Taylor, Gilmartin
Group philip@gilmartinIR.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024